Compare Eli Lilly And Co (LLY) vs Vanguard S&P 500 ETF (VOO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Vanguard S&P 500 ETF — how do they compare? Eli Lilly And Co trades at $1,179.27 (market cap $1.04T), while Vanguard S&P 500 ETF trades at $715.59 (market cap $1.80T). The key difference: Vanguard S&P 500 ETF is the larger of the two by market cap, and Eli Lilly And Co pays a 0.59% dividend while Vanguard S&P 500 ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and Vanguard S&P 500 ETF for 55 Days on average.
| LLY | VOO | |
|---|---|---|
Market Cap | $1.04T | $1.80T |
Volume | 3,064,878 | 4,722,271 |
Sector | Health | Broad Market / Factor |
52-Week High | $1.28K | $716.17 |
52-Week Low | $799.57 | $580.93 |
Typical Hold Time | 93 Days | 55 Days |
Enterprise Value | $1.09T | — |
Dividend Yield | 0.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,169.93, down 1.58% on the day, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The company demonstrates exceptional profitability with 83.4% gross margins and 33.53% net income margins, supported by dominant positioning in weight-loss and diabetes treatments. Recent clinical trial successes for next-generation drugs and expanded FDA approvals reinforce growth prospects.
LLY presents compelling growth potential with analyst consensus target of $1,350 representing 15% upside, though elevated valuations (P/E 39.26) and increasing competition in obesity drugs pose risks. Strong institutional support (73% buy ratings) and positive pipeline developments support continued momentum, but investors should monitor execution risks and market saturation concerns.
VOO trades at $711.37, down 0.43% on the day, with a bullish technical signal from moving averages and neutral oscillators. The ETF maintains strong institutional support despite a 46.9% increase in short interest reported by Defense World on October 3, 2026. Recent news highlights VOO's role as a core holding for long-term wealth building, with dividend payments scheduled for September 30, 2026.
VOO offers diversified exposure to S&P 500 companies with strong earnings growth projections of 35% for 2026. While short-term volatility may persist amid Federal Reserve policy uncertainty, the ETF remains well-positioned for investors seeking broad market participation. Key risks include potential earnings growth deceleration to 15% in 2027 and broader market valuation concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Vanguard S&P 500 ETF
VOO is a foundational ETF that tracks the S&P 500 Index, providing exposure to 500 of the largest and most established companies in the United States. Renowned for its ultra-low expense ratio and tax efficiency, it serves as a core building block for long-term investors seeking to capture the total return of the U.S. large-cap market in a single, highly liquid vehicle.
Read more on VOO →
